This inventor holds 1 USPTO granted patent. Top assignee: Sph Xing Ling Sci. & Tech. Pharmaceutical Co., Ltd.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: **Qin Shen: Innovator in Ketone Ester Pharmaceuticals**
Introduction
Qin Shen, an accomplished inventor based in Shanghai, China, has made significant contributions to the field of pharmaceuticals. His innovative work focuses on developing a novel ketone ester bulk drug, showcasing his commitment to advancing medical research and drug preparation methods.
Latest Patents
Qin Shen holds a patent for his invention titled "Extract of Leaves and Preparation Method Therefor." This patent emphasizes a method for preparing high-quality ketone ester bulk drugs. The disclosed method not only results in a stable quality of the ketone ester but also ensures a low unqualified rate and consistent quality across different batches. This innovation stands out when compared to traditional methods, providing a more effective solution for pharmaceutical applications.
Career Highlights
Qin Shen works with Sph Xing Ling Scientific & Technological Pharmaceutical Co., Ltd., where he contributes his expertise in pharmaceutical sciences. His career is marked by a dedication to improving drug formulation processes, and his singular patent reflects a pivotal advancement in the industry.
Collaborations
Qin Shen collaborates with notable coworkers Jun Wang and Qi Gao, who support his innovative initiatives within their company. These collaborative efforts enhance the development and refinement of pharmaceutical products, ultimately benefiting the broader medical community.
Conclusion
With his innovative spirit and important contributions to the field of pharmacology, Qin Shen exemplifies the role of inventors in shaping the future of medicine. His patent for a method of preparing ketone ester bulk drugs not only highlights his expertise but also marks a critical step forward in drug development, promising improved stability and quality for healthcare applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile